

Treatment Appraisal: Decision Summary

Date	13 th November 2012
Appraisal	Perampanel (Fycompa®) for focal epilepsy
Details	The NHS North East Treatment Advisory Group was requested to conduct an appraisal of and issue a recommendation regarding the use of perampanel for the treatment of partial-onset (focal) seizures in epilepsy in-line with the product license.
Recommendation	<p>The NHS North East Treatment Advisory Group recommends perampanel for partial (focal) seizure epilepsy only when other treatment options recommended by NICE have been tried or fully considered.</p> <p>The group recommends that perampanel should only be initiated by specialists.</p>
Clinical evidence summary	The group acknowledged that perampanel had been evaluated in a robust clinical programme although the group was disappointed with the relatively short duration of the observation period and the absence of an active treatment comparator. The group was satisfied that perampanel could have substantial and important clinical benefits for some, but not all, patients. The group noted the high rate of adverse effects although acknowledged that this was observed in a refractory patient population with high levels of concomitant medication use and that most adverse effects were mild or moderate in severity.
Cost analysis summary	Perampanel is available in a range of unit doses at a fixed cost. The cost of treatment is £1,825 per patient per annum regardless of dose. The perampanel mean cost per patient per annum was estimated to be more than all other anti-epileptic drugs licensed or recommended for focal epilepsy. The perampanel maximum cost per patient per annum was estimated to be less than some other anti-epileptic drugs used for focal epilepsy.
Financial impact	An estimate of the number of patients within NHS North East was made based on the uptake of other recent new anti-epileptic drugs.
PbR: Excluded	After four years it was estimated that 85 patients would be treated with perampanel at an annual cost of about £155,000.
Further research or information	

Not to be used for commercial or marketing purposes